期刊
GYNECOLOGIC ONCOLOGY
卷 166, 期 1, 页码 117-125出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2022.05.005
关键词
Carcinosarcoma; Homologous-recombination-deficiency(HRD); Poly(ADP-ribose)-polymeraseinhibitors; (PARPi); Whole-exome-sequencing(WES)
资金
- NIH [U01 CA176067-01A1]
- Deborah Bunn Alley Foundation [CA-16359]
- Cure Foundation
- Guido Berlucchi Foundation
- Gilead Sciences Inc., Foster City, CA
- NIH from NCI
- Standup-to-cancer (SU2C) convergence grant 2.0
The study found that ovarian and uterine carcinosarcoma with HRD signature were more sensitive to olaparib. The experiments showed that olaparib inhibited the growth of carcinosarcoma cells by blocking the cell cycle and inducing apoptosis. In the xenograft experiment, olaparib significantly suppressed the growth of HRD carcinosarcoma and improved overall survival.
Objectives. Carcinosarcoma (CS) of the ovary and uterus are highly aggressive malignancies associated with poor survival. Poly(ADP-ribose)-polymerase inhibitors (PARPi) are targeted agents impairing DNA repair via homologous-recombination-deficiency (HRD) mechanisms. We used whole-exome-sequencing (WES) data from a cohort of fresh tumor samples of ovarian (OCS) and uterine carcinosarcoma (UCS), primary cell lines and xenografts to investigate the role for olaparib in CSs. Methods. WES data from 73 CS samples (48 UCS and 25 OCS) were analyzed for HRD signatures. Olaparib activity was evaluated using cell-viability, cell-cycle, apoptosis and cytotoxicity assays against primary CS cell lines. Olaparib antitumor activity was tested in vivo against HRD CS xenografts. Results. Signature-3 (i.e. HRD-related signature) was identified in 60% of OCS (15 of 25) vs 25% of UCS (12 of 48) (p = 0.005). CS cell lines harboring Signature-3/HRD (3 OCS/1 UCS) were significantly more sensitive to olaparib when compared to HRP cell lines (5 UCS/1 OCS) [mean IC50 +/- SEM = 2.94 mu M +/- 0.07 vs mean +/- SEM = 23.3 mu M +/- 0.09, (p = 0.02), respectively]. PARPi suppressed CS cell growth through cell cycle arrest in the G2/M phase and caused more apoptosis in HRD vs HRP primary tumors (p < 0.0001). In vivo, olaparib significantly impaired HRD CS xenografts tumor growth (p = 0.0008) and increased overall animal survival (p < 0.0001). Conclusions. OCS and UCS cell lines harboring HRD signature-3 were significantly more sensitive to olaparib in vitro and in vivo when compared to HRP CS. Clinical studies with PARPi in CS patients with a dominant signature 3 (HRD-related) are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据